- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Interventions
- Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS)
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 9,121
matching trials from the live ClinicalTrials.gov search.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab
- Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
- Interventions
- cyclosporine, pravastatin sodium, mitoxantrone hydrochloride, etoposide, bone marrow aspiration
- Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- CAR2 Anti-CD38 A2 CAR-T Cells
- Biological
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • New York, New York + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- paclitaxel-loaded polymeric micelle
- Drug
- Lead sponsor
- Theradex
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 5
- States / cities
- Bonita Springs, Florida • Skokie, Illinois • Lafayette, Louisiana + 2 more
- Conditions
- Bladder Cancer
- Interventions
- ADXBLADDER
- Diagnostic Test
- Lead sponsor
- Arquer Diagnostics Ltd
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Daytona Beach, Florida • Jeffersonville, Indiana + 10 more
- Conditions
- Leukemia
- Interventions
- cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 30
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 23 more
- Conditions
- Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Peripheral Blood Stem Cell Transplantation
- Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Ovarian Cancer
- Interventions
- aldesleukin, p53 peptide vaccine, in vitro-treated peripheral blood stem cell transplantation
- Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Cancer
- Interventions
- CRLX101, Paclitaxel
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Columbus, Ohio + 4 more
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- mistletoe extract, gemcitabine hydrochloride
- Dietary Supplement · Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Interventions
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, biopsy
- Biological · Procedure
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- gemcitabine hydrochloride, carboplatin, dexamethasone, rituximab
- Drug · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, paclitaxel, topotecan hydrochloride
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2001
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- dexamethasone, floxuridine, fluorouracil, leucovorin calcium, laparotomy, conventional surgery
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 11
- States / cities
- Cedar Rapids, Iowa • Des Moines, Iowa • Papillion, Nebraska + 5 more
- Conditions
- Neoplasms
- Interventions
- ADH -1 (Exherin™)
- Drug
- Lead sponsor
- Adherex Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Fort Myers, Florida • Chapel Hill, North Carolina • Durham, North Carolina + 2 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Myelodysplastic/Myeloproliferative Neoplasms, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- 7-hydroxystaurosporine, perifosine, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Gliosarcoma, Recurrent Glioblastoma
- Interventions
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- Diagnostic Test
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Castro Valley, California + 43 more
- Conditions
- Pancreatic Cancer
- Interventions
- genistein, erlotinib hydrochloride, gemcitabine hydrochloride
- Dietary Supplement · Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 21 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Paranasal Sinus, Head and Neck Squamous Cell Carcinoma, Squamous Cell Cancer, Head and Neck Carcinoma
- Interventions
- Nivolumab, Cetuximab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Atlanta, Georgia • Columbus, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Durvalumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 8
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Recurrent Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- eribulin mesylate
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, High Grade Ovarian Serous Adenocarcinoma
- Interventions
- gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab
- Biological · Drug
- Lead sponsor
- TCR2 Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 10
- States / cities
- San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more